Compare Neurocrine Biosciences Inc (NBIX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Utilities Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Utilities Select Sector SPDR Fund trades at $44.98. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NBIX | XLU | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | — |
52-Week High | $180.55 | $47.73 |
52-Week Low | $123.10 | $41.31 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
XLU trades at $44.93, down 0.51% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The ETF benefits from strong AI-driven power demand tailwinds, positioning utilities as growth plays amid sector rotation. Recent news highlights its role in the AI infrastructure boom, with defensive characteristics attracting investors during tech volatility.
Outlook is positive due to structural electricity demand growth from AI data centers, though regulatory risks and execution challenges remain. The ETF offers stable dividends and exposure to regulated utilities, with Wall Street sentiment leaning bullish on earnings potential. Key risks include grid capacity constraints and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
